PDF herunterladen
Drug Res (Stuttg) 2013; 63(11): 602
DOI: 10.1055/s-0033-1357211
Erratum
© Georg Thieme Verlag KG Stuttgart · New York

Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen

Autoren

  • B. Bittner

    1   F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland
    2   F. Hoffmann-La Roche Ltd., Pharma Medicines Global Product Strategy, Basel, Switzerland

  • W. F. Richter

    3   F. Hoffmann-La Roche Ltd., Nonclinical Safety, Basel, Switzerland

  • F. Hourcade-Potelleret

    4   F. Hoffmann-La Roche Ltd., Clinical Modeling & Simulation, Basel, Switzerland

  • C. McIntyre

    1   F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland

  • F. Herting

    5   Roche Diagnostics GmbH, Penzberg, Germany

  • M. L. Zepeda

    6   Halozyme Therapeutics Inc., San Diego, CA, USA

  • J. Schmidt

    2   F. Hoffmann-La Roche Ltd., Pharma Medicines Global Product Strategy, Basel, Switzerland
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
10. Oktober 2013 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Originalartikel zu diesem Erratum:

Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing RegimenDrug Res (Stuttg) 2012; 62(09): 401-409
DOI: 10.1055/s-0032-1321831

Erratum

Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen

B. Bittner, W. F. Richter, F. Hourcade-Potelleret, C. McIntyre, F. Herting, M. L. Zepeda, J. Schmidt

Arzneimittelforschung 2012; 62: 401–409

DOI: 10.1055/s-0032-1321831

The references referring to other sections like “Section 6.4“ are no longer valid as the new formatting removed the numbers for the different paragraphs in the article.